Rituximab is a Medicine belongs to Antineoplastic group whose information about Brand can be referenced from   Book : Martindale    Page : 848   Edition : 37  

  ►   Brandname : Redutux, Mab Thera
  ►  Strength : Injection with 10 mg/ml. 

Reference of this Medicine for its Strength can be taken from   Book : Basic & Clinical pharmacology    Page : 656   Edition : 12  
A Route of administration in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration.

  ►  Route of administration : IV
Reference :-   Book : Martindale    Page : 845   Edition : 37  

Dosing of Medicine differ in Adult & Pediatrics ↓

Adult Dose

S.No Ailment   Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency   Additional Info
1 Refactory or replased folicular lymphoma IV 357 mg/m2 Injection Dose: once weekly for 4 doses; in the USA 8 doses may be given. Patients in either country may be re-treated after relapse for a further 4 doses. When given with combination chemotherapy such as CVP (for follicular lymphoma) or CHOP (for diffuse large B-cell lymphoma), rituximab 375 mg/m2is given on day 1 of the chemotherapy cycle, after the corticosteroid component of the regimen, for a total of 8 cycles. In patients previously treated with 6 to 8 cycles of CVP chemotherapy and who have not progressed, rituximab 375 mg/m2 may be given once weekly for 4 doses, repeated every 6 months, for up to 16 doses. For maintenance treatment in those who have responded to induction chemotherapy, rituximab 375 mg/m2 is given once every 3 months until disease progression or for a maximum period of 2 years.
2 Chronic lymphocytic leukaemia IV 375 mg/m2 Injection Dose: Dose: Given on the day before chemotherapy in cycle 1, followed by 500 mg/m2 given on day 1 of each subsequent cycle, for up to 6 cycles in total; chemotherapy is given after the rituximab infusion. Prophylactic hydration and allopurinol or rasburicase is recommended, starting 48 hours before rituximab, to reduce the risk of tumor lysis syndrome; in some countries, those with high lymphocyte counts are given intravenous corticosteroids before rituximab to reduce the incidence and severity of infusion reactions.
3 Rheumatoid arthiritis IV 1 gm Injection Dose: the infusions are separated by 2 weeks. It is given with methotrexate, and corticosteroids are recommended before each infusion to reduce the incidence and severity of infusion reactions.

Ref :-  Book : Martindale    Page : 846   Edition : 37  

Pediatric Dose

S.No Ailment   Age Min   Age Max   Weight ( Kg ) Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency  Additional Info  
1 Auto-immune haemolytic anaemia, idiopathic thrombocytopenic purpura and post-transplantation lymphoproliferative disease, as well as rheumatoid arthritis, and SLE IV 375 mg/m2 Injection

Ref :- Book : Martindale    Page : 846   Edition : 37  
►  Side Effect : Fever, Chills, Throat itching, Urticaria, Neutropenia, Conjunctivitis, Bowel obstruction, Pulmonary reaction, Progressive multifocal leukoencephalopathy, Mild hypotension
Ref :-   Book : Martindale    Page : 845   Edition : 37.  

►  Drug Interaction : Drug interaction of Rituximab is with NA

  ►    Mechanism of Drug Drug Interaction :  Rituximab is indicated for the treatment of moderately to severely active rheumatoid arthritis in combination with methotrexate in patients with an inadequate response to one or more TNF-α antagonists. Statins decreased rituximab cytotoxicity. Ref: Martindale pg no 846 ed 37.
Ref :-   Book : Basic & Clinical pharmacology    Page : 646   Edition : 12.  

►  Contraindication : Extensive tumour burden, Pulmonary tumour infiltration
Ref :-   Book : Martindale    Page : 845   Edition : 37.  
  ►  Mechanism of Action :   Rituximab is a chimeric monoclonal antibody biologic agent that targets CD20 B lymphocytes. This depletion takes place through cell-mediated and complement-dependent cytotoxicity and stimulation of cell apoptosis. Depletion of B lymphocytes reduces inflammation by decreasing the presentation of antigens to T lymphocytes and inhibiting the secretion of proinflammatory cytokines. Rituximab rapidly depletes peripheral B cells, although this depletion correlates neither with efficacy nor with toxicity.
Ref :-   Book : Basic & Clinical pharmacology    Page : 646   Edition : 12.  

Pathway of DIETARY Product

​   ► Act.Comp / Nutrient / Food / Herb as follows :- Cancer tree with Another pathway.  

  ►  Pathway with its reference as follows :-
  • Camptotecin have anticancer effect --- (Kokate, C.K. and A.p. Purohit. Pharmacognosy. Nirali prakashan: Chennai, 2013. Print. )

  •   ►  URL --
  • http://freepharmadownloads.blogspot.com/2013/02/pharmacognosy-ckkokate-free-download.html .

  • DIETARY Substance Interactions

    ​   ► This Medicine interact with :- NA

    ContraIndication DIETARY Substance

    ​   ► This Medicine contraindicate with :- NA

    ►   Route of Elimination :   NA

    ►    Plasma Half-life :   Min value :-   20 days,    Max value :-   NA
    Ref :-   Book : Martindale    Page : 846   Edition : 37.  

    ►    Peak Plasma Concentration :   Min value :-   NA    Max value :-   NA